Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
about
Tau PET imaging: present and future directions.Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.Imaging and fluid biomarkers in frontotemporal dementia.Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?Imaging tau pathology in Parkinsonisms.The emerging role of PET imaging in dementia.18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.New advances in tau imaging in parkinsonism.[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy.Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau.Small-molecule PET Tracers for Imaging Proteinopathies.PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms.Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech.Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration.Molecular imaging: What is right and what is an illusion?Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology.Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding.Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy.Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?The development and validation of tau PET tracers: current status and future directionsImaging Protein Misfolding in the Brain Using β-Sheet Ligands[F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review
P2860
Q34680852-DB0AFBDE-2637-4D46-B651-B6C48EEC9A91Q37731710-F1215B45-99AA-464D-93BA-0C060F3F9C95Q38640294-BAE17D28-0D67-4FB4-84FB-82F4E3242135Q38670219-8E969033-D489-4660-8C1C-44E8D4B3B37EQ39303669-45CF7F4B-3C1A-4E81-ADA1-B6EE8D383D0DQ39419877-8EDA7CD2-15B4-41A0-A156-55D7330BCD1AQ42701971-566737A0-6789-4339-8CBB-EA755E9C3295Q46616293-90D94333-A38A-471A-ABBB-1232BD196B16Q47140361-41A7D06C-813F-46A6-A4F5-33462A32BEDFQ47329627-50FA7A13-B24D-436E-8EBB-EF9DFFD78F92Q47547648-71F8136A-A92F-42A7-AB44-9B5382AD6286Q47739900-C6FE2018-D124-434B-B62F-CDE6C16A59A5Q47926474-E3315FEA-237F-4804-8E78-33CAC6417A79Q48346682-8AF43BA4-A18A-479B-BD6C-9DEA31027B7DQ49295547-18C0F0F1-E17B-44AB-A8F9-6ED2B0F08D7EQ49900567-0161065C-DC9D-4A78-A310-6CE3BDF20974Q52344625-DC00A8DD-A923-4025-9200-2643E6ABBAFAQ55031324-83DA18BB-97DB-4D48-987D-FEA78EF7FAD3Q55254017-6BB1035C-5BED-4912-ADCF-E91242CC317CQ55339752-F705661C-1C46-421C-B921-3F1BECC01CD7Q55416644-12BAFAD1-2EA0-463F-8DDA-D10DC224E4E7Q55494083-0CE857A3-B608-4B03-8D99-D67700E2CC76Q55497377-A2EF9588-35AE-42CA-90AF-D9BCCEF6A2D6Q56594907-1B467077-5761-46BA-AD57-787B45676B9FQ57168250-E469DFB6-E680-4CB4-8AC2-6673CF5B4122Q58794629-B2D6148B-30A2-4B13-B03B-1F79CDC0C9A7
P2860
Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
@en
Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
@nl
type
label
Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
@en
Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
@nl
prefLabel
Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
@en
Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
@nl
P2093
P2860
P356
P1476
Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.
@en
P2093
K Furukawa
S Furumoto
V L Villemagne
P2860
P304
P356
10.1111/ENE.13164
P577
2016-10-31T00:00:00Z